Facebook
Twitter
LinkedIn
Forward
Managing Drug-Related Dermatologic Reactions in Patients with Cancer - A Focus on Immunotherapy and Targeted Therapies
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes
Dermatologic adverse effects are among the most common conditions associated with immunotherapy and targeted therapy. Cutaneous conditions in cancer patients can affect the skin, hair, nails, and mucosae. In this webcast, expert faculty will review the most common cutaneous reactions associated with immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), and recommend strategies to treat and prevent potential adverse effects. Dermatologists should be part of the oncological care team in order to assist in appropriately diagnosing drug-related cutaneous reactions and offer skin-directed approaches to efficiently treat these reactions, enabling patients to remain on cancer therapy when possible.
Target Audience
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
Learning Objectives
1. Review the most common cutaneous reactions associated with immune checkpoint inhibitors and tyrosine kinase inhibitors and institute strategies to treat and prevent them
2. Characterize drug-related cutaneous reactions that require involvement of both the dermatologist and APP/oncologist and develop a team-based treatment plan
Faculty
Johnathan Leventhal MD
Jonathan Leventhal, MD, is the director of the Onco-Dermatology Program at Smilow Cancer Hospital at Yale New Haven. He treats patients undergoing cancer treatment who experience itchy or painful rashes, as well as hair and nail changes that can result from either their disease or treatment, including chemotherapy, immunotherapy, radiation or stem cell transplantation.
In addition to his role at Smilow, Dr. Leventhal, an assistant professor of dermatology and associate director of the residency program at Yale School of Medicine, cares for patients with a wide range of skin conditions in Yale Medicine Dermatology’s New Haven and Branford locations. He performs routine skin cancer screening examinations and also treats general skin problems—from acne to psoriasis to eczema. He is also the Associate Residency Program Director and is Principal Investigator of several clinical trials involving the management of cutaneous reactions to cancer therapy.
DISCLOSURES:
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Johnathan Leventhal has served on Advisory Boards for Sanofi-Regeneron and La Roche-Posay. He has received funding for clinical trials from Azitra, Inc., and OnQuality during the past 24 months.
Available Credit
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Price
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form.
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
DISCLOSURE OF UNLABELED USE:
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER:
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.